Clinical Trial Update: DAratumumab and REvlimid REfractory MM

View source ↗

Summary

A clinical trial evaluating daratumumab in combination with lenalidomide (Revlimid) for relapsed/refractory multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)
• Revlimid (lenalidomide)

Snippet

Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia | Conditions: Multiple Myeloma | Status: RECRUITING